title: Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine.
abstract: Ado-trastuzumab emtansine (T-DM1) is a novel antibody-drug conjugate with current FDA recommendation for second-line treatment of HER-2-positive metastatic breast cancer. It is a human epidermal growth factor receptor (HER-2)-targeted antibody-drug conjugate composed of trastuzumab, a stable thioether linker, and the potent cytotoxic agent DM1 (derivative of maytansine). Ado-trastuzumab emtansine improved both progression-free and overall survival as reported in EMILIA trial. With ongoing clinical trials in adjuvant and first-line setting for HER-2-positive early and metastatic breast cancer, it is prudent to recognize, report, and treat any adverse events related to T-DM1. We report a case of acute pancreatitis in a 54-year-old woman with metastatic breast cancer after she received her first dose of ado-trastuzumab emtansine. To the best of our knowledge, this is the first reported case of acute pancreatitis with probable association with ado-trastuzumab emtansine.
authors.affiliation: Departments of 1Hematology/Oncology and 2Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC.
authors.forename: Mahvish
authors.initials: M
authors.lastname: Muzaffar
authors.forename: Jingquan
authors.initials: J
authors.lastname: Jia
authors.forename: Darla
authors.initials: D
authors.lastname: Liles
authors.forename: Musharraf
authors.initials: M
authors.lastname: Naveed
authors.forename: Anita
authors.initials: A
authors.lastname: Kumari
mesh_terms: D000208:Acute Disease; D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008453:Maytansine / Q000009:adverse effects / Q000031:analogs & derivatives*; D008875:Middle Aged; D010195:Pancreatitis / Q000139:chemically induced*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine